SENTARA HEALTH PLANS

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid)</u> on this request. All other information may be filled in by office staff; <u>fax to 1-800-750-9692</u>. No additional phone calls will be necessary if all information <u>(including phone and fax #s)</u> on this form is correct. <u>If the information provided is not complete, correct, or legible, the authorization process can be delayed.</u>

<u>Drug Requested</u>: **Tryvio**[™] (aprocitentan)

MEN	MBER & PRESCRIBER INFO	ORMATION: Authorization may be delayed if incomplete.
Memb	er Name:	_
Member Sentara #:		Date of Birth:
Prescr	iber Name:	
Prescr	iber Signature:	Date:
Office	Contact Name:	
		Fax Number:
NPI #:		
DRU	G INFORMATION: Authoriza	ation may be delayed if incomplete.
Drug N	Name/Form/Strength:	
Dosing Schedule:		Length of Therapy:
Diagnosis:		ICD Code, if applicable:
Weight (if applicable):		Date weight obtained:
Quan	tity Limit: 1 tablet per day	
suppo		ow all that apply. All criteria must be met for approval. To on, including lab results, diagnostics, and/or chart notes, must be
Initia	al Authorization: 12 months	
	Member is 18 years of age or older	
	agent from each of the classes below	nent at maximum or maximally tolerated doses with at least <u>ONE</u> , unless contraindicated, for the past 4 weeks (verified by ation of intolerances or contraindications must be submitted;
	□ calcium channel blockers (e.g., a	inhibitors (e.g., lisinopril, enalapril, losartan, valsartan) mlodipine, felodipine, nifedipine, verapamil) e.g., hydrochlorothiazide, chlorthalidone, indapamide)

(Continued on next page)

	Treatment with a mineralocorticoid receptor antagonist (spironolactone, eplerenone) has been added to the existing antihypertensive regimen and was ineffective, intolerable, or is contraindicated (verified by pharmacy paid claims; documentation of intolerance or contraindication must be submitted)		
	Treatment with an additional antihypertensive agent with a different mechanism of action (e.g., hydralazine, minoxidil, clonidine, prazosin, metoprolol) has been ineffective, or are all contraindicated (verified by pharmacy paid claims; documentation of intolerance or contraindication must be submitted)		
	Provider must list the member's current prescribed antihypertensive drug regimen:		
	Member has been adherent to prescribed antihypertensive drug regimen for at least 4 weeks prior to the date of the blood pressure reading recorded in chart note documentation (adherence will be verified by pharmacy paid claims)		
	Provider has evaluated the member for causes of pseudoresistance (e.g., inaccurate blood pressure readings, white coat hypertension, secondary hypertension, non-adherence to medication) and confirms that pseudo-resistant hypertension has been ruled out		
	Member has resistant hypertension as demonstrated by blood pressure above 130/80 mmHg, despite adherence to prescribed antihypertensive drug regimen (submit documentation of blood pressure reading recorded within 30 days of request)		
	For patients who can become pregnant, all provider and patient-specific requirements of Tryvio [™] REMS have been satisfied		
	Provider attests baseline liver function tests and hemoglobin levels have been obtained and will be monitored periodically or as clinically indicated		
suppo	uthorization: 12 months. Check below all that apply. All criteria must be met for approval. To ort each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be ded or request may be denied.		
	Member's blood pressure has reduced from baseline after initiating therapy with Tryvio [™] (submit documentation)		
	Member is adherent to Tryvio [™] and continues to receive Tryvio [™] in addition to background antihypertensive drug therapy (verified by pharmacy paid claims)		
	Provider attests hemoglobin and liver function tests continue to be monitored		
Med	lication being provided by Specialty Pharmacy – Proprium Rx		

**Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. **

*Previous therapies will be verified through pharmacy paid claims or submitted chart notes. *